|
May 27
|
3 Value Stocks with Questionable Fundamentals
|
|
May 24
|
Does the 23andMe Acquisition Make Regeneron a Buy Now?
|
|
May 23
|
Regeneron announces initial results from two cohorts of LINKER-MM2 trial
|
|
May 23
|
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
|
|
May 23
|
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
|
|
May 23
|
Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Promising Results In LINKER-MM2 Trial For Linvoseltamab
|
|
May 23
|
Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them.
|
|
May 22
|
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
|
|
May 22
|
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim Cramer
|
|
May 21
|
Viz.ai, Sanofi and Regeneron to link for COPD management
|
|
May 21
|
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
|
|
May 21
|
3 Cash-Producing Stocks in Hot Water
|
|
May 20
|
S&P 500 Gains and Losses Today: FICO Stock Falls as Federal Housing Official Questions Pricing
|
|
May 20
|
Regeneron Pharmaceuticals (NasdaqGS:REGN) Partners With Viz.ai For AI-Powered COPD Solutions
|
|
May 20
|
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
|
|
May 20
|
Evercore says 23andMe buyout removes downside case for OraSure
|
|
May 20
|
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
|
|
May 20
|
Jamie Dimon’s Tariffs Warning Should Have Rocked Markets. Why He’s Being Ignored.
|
|
May 19
|
Regeneron to acquire bankrupt genetic tester 23andMe
|
|
May 19
|
Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
|